Skip to main content

and
  1. No Access

    Article

    Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome

    Smith-Lemli-Opitz syndrome (SLOS) is an inborn error of cholesterol biosynthesis characterized by developmental delay and multiple malformations.Some of the patients have skin photosensitivity and therefore te...

    M. Rossi, G. Federico, G. Corso, G. Parenti in Journal of Inherited Metabolic Disease (2005)

  2. No Access

    Article

    HHH syndrome (hyperornithinaemia, hyperammonaemia, homocitrullinuria), with fulminant hepatitis-like presentation

    We report a 3-year-old Italian patient with the hyperornithinaemia, hyperammonaemia, homocitrullinuria (HHH) syndrome who presented with neurological deterioration after an intercurrent infection. Hyperammonae...

    S. Fecarotta, G. Parenti, P. Vajro, A. Zuppaldi in Journal of Inherited Metabolic Disease (2006)

  3. No Access

    Article

    Myasthenia gravis in a patient affected by glycogen storage disease type Ib: A further manifestation of an increased risk for autoimmune disorders?

    Glycogen storage disease type Ib (GSD Ib, OMIM 232220) is an inborn disorder of glucose metabolism, caused by mutations in the G6PT gene, encoding a glucose 6-phosphate transporter (G6PT). GSD Ib is mainly associ...

    D. Melis, F. Balivo, R. Della Casa, A. Romano in Journal of Inherited Metabolic Disease (2008)

  4. No Access

    Article

    Vitamin E supplementation improves neutropenia and reduces the frequency of infections in patients with glycogen storage disease type 1b

    Neutropenia and/or neutrophil dysfunction are part of glycogen storage disease type 1b (GSD1b) phenotype. Recent studies indicated that activation of apoptosis and increased reactive oxygen species are implica...

    D. Melis, R. Della Casa, R. Parini, M. Rigoldi in European Journal of Pediatrics (2009)

  5. No Access

    Article

    Desensitization of two young patients with infantile-onset Pompe disease and severe reactions to alglucosidase alfa

    Pompe disease is a metabolic myopathy, due to deficiency of alpha glucosidase, with a wide clinical spectrum. Enzyme replacement therapy is the only available treatment to improve morbidity and mortality, espe...

    V. Gragnaniello, S. Fecarotta, A. Pecoraro, A. Tarallo, A. Catzola in Neurological Sciences (2019)